A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

• Status: Not yet recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Enliven Therapeutics

Criteria

Inclusion Criteria:

• CML that has failed or the patient is intolerant to available therapies known to be active for treatment of their CML.

• ECOG performance status of 0 to 2.

• Adequate hematologic, hepatic and renal function.

Exclusion Criteria:

• Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.

• QTc >470 ms.